TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Core Insights - Tvardi Therapeutics, Inc. experienced a significant decline in its stock price, dropping over 80% following disappointing preliminary data from its Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis [2]. Company Overview - Tvardi Therapeutics, Inc. is currently under investigation by Faruqi & Faruqi, LLP for potential claims related to the substantial losses suffered by investors due to the recent stock price drop [1][3]. Clinical Trial Results - The Phase 2 REVERT clinical trial aimed to evaluate the safety, pharmacokinetics, and exploratory outcomes related to lung function of TTI-101. However, the preliminary data indicated that the study did not meet its goals, particularly in terms of changes in Forced Vital Capacity (FVC) [2]. - The preliminary data showed that the baseline characteristics of patients were similar across treatment arms, except for the percent predicted FVC, which was lower in the placebo group compared to the TTI-101 group [2].